T h17 cells are important mediators
of autoimmunity, yet the mechanisms by which they are controlled are not fully understood. Studies in mice, including a recent article in Nature Immunology by Yang et al., show that IL-2 is an important inhibitory factor for the differentiation of Th17 cells, inducing phosphorylation of STAT5, which outcompetes STAT3 binding at the IL-17 locus. In humans however, IL-2 appears to be crucial for Th17 differentiation, yet inhibits the expansion of antigen-specific Th17 clones, again via a STAT5 mechanism. Here we discuss how the article by Yang et al. offers a novel mechanism to explain how changes in the balance of different cytokines in the inflammatory environment may alter the stability or phenotype of regulatory T cells and T helper cell subsets.
It is widely accepted that T helper (Th) 1 cells and perhaps more so, Th17 cells are the key mediators of T cell pathogenesis in autoimmune disorders including multiple sclerosis, rheumatoid arthritis and colitis. When helper T cell subsets were first described, they were considered to be mutually exclusive. In the presence of IL-12, naïve T cells were shown to express STAT4 and T-bet and produce IFNc. Th2 cells could be induced in the presence of IL-4 via the upregulation of GATA-3 and STAT6. 1 Moreover, the ectopic expression of T-bet in polarized Th2 cells resulted in the production of IFNc and the suppression of Th2 cytokines. 2 Later, the discovery of Th17 cells expressing STAT3 and RORct also appeared to demonstrate a phenotype distinct from Th1 or Th2 cells. 3 The first studies to question this distinct irreversible fate involved CD4 + regulatory T cells (Tregs). Production of TGF-β in the absence of inflammation led to the development of Tregs; however in the presence of inflammatory cytokines such as IL-6 and IL-1β the differentiation of Th17 cells dominated. 4 This suggested that the Th17 phenotype was particularly sensitive to environmental cues. Indeed recent literature has identified cells producing both IL-17 and cytokines associated with other T helper cell subsets. These Th17 "dual producers" are seen most frequently in inflammatory disease settings, such as autoimmunity 5 or allergy. 6 Moreover, the adoptive transfer of Th17 cells to lymphopenic mice drives the conversion of Th17 cells to IFNc producers and triggers an IFNc-mediated diabetes. 7 For many years, it has been recognized that IL-2 plays a key role, not only in the expansion and proliferation of T cells, but also in the development and function of Tregs. In 2007, a new role for IL-2 was reported: its ability to inhibit Th17 differentiation. 8 A more recent publication by Yang et al. investigated the mechanism of this inhibition. 
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Although IL-2 inhibits the production of IL-17 and IL-22 by CD4 + T cells, the expression of the Th17 transcription factor RORct was only slightly reduced. This suggests IL-2 does not mediate its suppressive effect through the inhibition of RORct expression, and indeed, overexpression of RORct by CD4 + T cells did not prevent the capacity of IL-2 to suppress Th17 differentiation.
STAT3 promotes the production of IL-17 by binding to specific sites within the IL-17 a-f locus. Yang et al. show that STAT5 can compete for these STAT3 binding sites. This means that in the presence of IL-2, STAT5 binding to the IL-17 locus prevents the binding of STAT3 and its enhancer elements, inhibiting production IL-17. In addition, STAT5 can modify the IL-17 locus, altering the acetylation of specific histones, partly through the recruitment of NCOR2, a histone deacetylator adaptor protein.
The ability of IL-2 to inhibit Th17 differentiation through the STAT5-mediated displacement of STAT3 from the IL-17 locus is an exciting finding. Recently, STAT5 has also been shown to negatively regulate the development of T follicular helper cells (TFH). TFH cells are crucial for the development of germinal centers and expansion of their numbers has been associated with the development of autoantibodies in a lupus model.
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Similar to Th17 cells, TFH cell development is dependent on IL-6 and STAT3, but also requires IL-21 and expression of Bcl-6. Two studies now reveal that in response to IL-2, STAT5 signals result in the upregulation of Blimp-1, leading to a repression of Bcl-6 and a reduced development of TFH cells. 16, 17 It would be interesting to discover whether STAT3 binds regions of the Bcl-6 locus and determine whether repression of TFH cell development is only via the active production of Blimp-1 or due to competition between STAT3 and STAT5 for binding sites in the Bcl-6 gene locus.
Many genes are now known to be regulated by more than one STAT. It is interesting however that STATs can act, not only as promoters of gene expression, but also as repressors via the displacement of activating STATs and the recruitment of histone deacetylases. As Yang et al. describe, the cytokine environment and the specific gene locus both contribute to whether the gene is transcribed or repressed. For example, when there is an environment of low IL-2 but high IL-6, STAT3 signals dominate and IL-17A and IL-17F are produced. However in an environment of high IL-2 and high IL-6, STAT5 maintains the capacity to act as a repressor for IL-17A. In contrast, under these conditions the displacement of STAT3 by STAT5 at the IL-17F locus is prevented.
This novel idea, that one STAT can displace another, raises the question of whether this is a specific property of STAT3 and STAT5 competition, or if other STATs also possess this function? As previously discussed, it has been known for many years that the cytokine environment can influence the development of T helper cell subsets. There is however, increasing interest in the propensity of T cells to switch from one lineage to another and this is particularly relevant to regulatory T cell stability. One might propose that STATs play a role in the switching of Tregs into Th17 cells or Th17 to Th1 cells if the balance of cytokines change in the environment, such as that during inflammatory disease (Fig. 1) . It has been known for many years that the control of Th17 differentiation can be dependent on Th1 cells and the production of IFNc. Indeed, IFNc can suppress the production of IL-17 by the activation of STAT1 and the upregulation of SOCS1 and SOCS3. 18 Furthermore, in an inflammatory environment with the balance of IL-2 and proinflammatory cytokines altered, regulatory T cells could convert to Th17 cells (Fig. 1) .
In humans however, the role of IL-2 in Th17 differentiation may differ to that in mice. IL-2 in combination with IL-1β, IL-23 and TGF-β differentiates human Th17 cells from naïve CD4 + T cells 19 and addition of IL-2 to healthy PBMC can enhance IL-17 production by memory CD4 + T cells 18 . These studies suggest a positive role for IL-2 in the differentiation and expansion of human Th17 cells. In contrast, IL-2 driven phosphorylation of STAT5 was shown to mediate a reduction in IL-17 production and RORct expression in re-stimulated human Th17 clones differentiated in the presence of microbial antigens. 20 T cell activation in the presence of IL-2 is key however for IL-1β, IL-23 and TGF-β to mediate the switching of a small proportion of human naïve Tregs into IL-17 producing T cells. 21 The role of IL-2 in Th17 differentiation and expansion is not completely understood, but whether IL-2 is simply required as an early signal to stimulate naïve T cells and thus permit responsiveness to cytokines that drive a Th17 phenotype, or whether the mechanism of Th17 lineage decision is indeed different between mice and humans will be interesting to explore in the future. What is becoming apparent from recent studies is that T helper cell differentiation and T cell switching is dependent on a balance between different cytokines in the environment, be it IL-2 and IL-6 or IL-1β and IL-12, rather than the presence or absence of particular cytokines and the signals they induce.
In conclusion, identifying the role of STATs in the activation and repression of specific genes in humans could be vital to understanding how inflammatory cell populations can be regulated and how the stability of different T helper and Treg populations can be controlled and manipulated in a disease setting. 
